VIALE-A: What the Leukemia Trial Found

The problem this trial addressed

Acute myeloid leukemia moves fast. Immature myeloid cells fill the bone marrow within weeks, crowding out the cells that carry oxygen, clot blood, and fight infection.

The treatment that offers the best chance of remission is intensive induction chemotherapy. It is brutal. It usually means weeks in hospital with very low blood counts, and it can be too risky for people with other serious health problems.

That leaves a large group stranded. SEER, the federal cancer surveillance program, records AML as most often diagnosed between ages 65 and 74. Many of those people cannot safely have intensive chemotherapy, whether because of age, heart or kidney disease, or both.

The trial report opens by calling their outlook dismal, even after a hypomethylating agent. VIALE-A asked whether adding a second drug to one of those agents would help.

Trial at a glance

The two drugs, in plain terms

Azacitidine is a hypomethylating agent. Cells switch genes off by attaching small chemical tags, called methyl groups, to DNA. Cancer cells use that mechanism to silence genes that would otherwise restrain them. Azacitidine strips the tags away, letting some of those genes switch back on. It was given on days 1 to 7 of each 28-day cycle, at an amount calculated from body size.

Venetoclax blocks BCL2, a protein that holds a cell's self-destruct switch shut. AML cells depend heavily on it to stay alive. The target dose was 400 mg, taken by mouth once a day.

Venetoclax is built up gradually at the start, under close blood monitoring, so the target figure is not where anyone begins.

The point of the pairing is that each one makes the other work better.

What the trial found

At a median follow-up of 20.5 months, median overall survival was 14.7 months with venetoclax added, against 9.6 months on azacitidine alone. That is a difference of 5.1 months.

The hazard ratio for death was 0.66, with a 95 percent confidence interval of 0.52 to 0.85 and p<0.001. The risk of dying at any given moment was about a third lower.

Remissions were much more common. Complete remission — no detectable leukemia with blood counts back to normal — occurred in 36.7 percent versus 17.9 percent, p<0.001. Composite complete remission, which also counts remissions where blood counts have not fully recovered, reached 66.4 percent versus 28.3 percent, p<0.001.

That is roughly a doubling of complete remissions and more than a doubling of the composite figure.

What it cost

Killing leukemia cells in the marrow means the marrow stops working for a while, and the trial reports that clearly.

Grade 3 or higher neutropenia occurred in 42 percent versus 28 percent. Febrile neutropenia — fever with a dangerously low white count — occurred in 42 percent versus 19 percent. Grade 3 or higher thrombocytopenia, meaning low platelets, occurred in 45 percent versus 38 percent. Infections of any grade occurred in 85 percent versus 67 percent. Serious adverse events occurred in 83 percent versus 73 percent. Nausea of any grade affected 44 percent versus 35 percent.

So this is not a gentle option. It is a less intensive one, with a real infection burden attached.

When to call the care team

During treatment for AML:

• A temperature of 100.4°F (38°C) or higher, or shaking chills: call your care team right away, at any hour. CDC calls a fever during chemotherapy a medical emergency. If you cannot reach the team, go to an emergency room or call 911 (CDC).
• Bleeding that will not stop, or sudden trouble breathing: call 911.
• Signs of infection such as a new cough, sore throat, or burning when passing urine: call your care team right away (CDC).

NCI lists the signs of AML as weakness or feeling tired, fever, infection, paleness, and easy bruising or bleeding (NCI). Our page on leukemia explains how it is tested for.

What this trial cannot tell you

• Everyone here was judged unfit for intensive chemotherapy. The result says nothing about people who can have it.
• A median of 14.7 months is a midpoint. Half of the group lived less than that, and some lived considerably longer.
• Follow-up was 20.5 months. Long-term outcomes were not what this analysis measured.
• The comparison was azacitidine alone. It was not a comparison against intensive chemotherapy or against a transplant.
• The infection rate is the trade. Anyone weighing this regimen should ask specifically about monitoring, hospital access, and antibiotic plans.
• SEER records five-year relative survival for AML at 33.4 percent for people diagnosed from 2016 through 2022, across all ages and all treatment intensities. It is a group average from people diagnosed years ago and describes populations, not individuals. Our page on what standard of care means in a trial explains why control arms date.

Sources

• N Engl J Med 2020: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A), PMID 32786187 — record retrieved via NCBI eutils
• ClinicalTrials.gov API v2 record for NCT02993523
• NCI SEER Cancer Stat Facts: Acute Myeloid Leukemia
• NCI: Leukemia—Patient Version
• NCI PDQ: Adult Acute Myeloid Leukemia Treatment (Patient Version)
• CDC: Watch Out for Fever

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.